<DOC>
	<DOCNO>NCT01129323</DOCNO>
	<brief_summary>The purpose study evaluate effectiveness allogeneic transplant reduced-intensity preparative regimen patient , evaluate survival , evaluate side effect treatment . The patient study two year treatment active monitoring . After treatment active monitoring , patient 's medical condition follow indefinitely .</brief_summary>
	<brief_title>Reduced-Intensity Preparative Regimen Allogeneic Stem Cell Transplantation Patients With Severe Aplastic Anemia</brief_title>
	<detailed_description>Aplastic Anemia blood disorder bone marrow produce enough cell blood . Patients aplastic anemia low count three blood cell type ( RBC , WBC , Platelet ) . Severe case aplastic anemia untreated lead death bleed overwhelming infection . For patient Severe Aplastic Anemia ( SAA ) , allogeneic hematopoietic stem cell transplant ( HSCT ) HLA-identical sibling accepted treatment restore normal bone marrow function . Preparative regimen allogeneic HSCT design give high tolerated dos chemotherapy , without total body irradiation ( TBI ) , order fully `` ablate '' destroy patient host 's bone marrow transplant cell HLA-identical sibling engraft patient host . While allogeneic HSCT proven curative form therapy SAA , also associate high transplant-related morbidity ( side effect ) possible mortality ( death ) . One toxic side effect high-dose chemotherapy TBI believe major contribute factor `` Graft-versus-Host Disease '' ( GVHD ) . Preliminary study show reduced intensity ( non-myeloablative ) allogeneic HSCT may effective treat SAA . Low-dose chemotherapy use instead high-dose chemotherapy TBI . Some small study indicate reduced intensity preparative regimen use Fludarabine Cyclophosphamide allow engraftment match sibling donor set acceptable level toxic side effect subject variety hematologic cancer . Additional study follow show reduced intensity preparative regimen include fludarabine , cyclophosphamide antithymocyte globulin , allow engraftment donor stem cell subject SAA acceptable engraftment rate decrease severity GVHD . This study design evaluate effectiveness allogeneic transplant reduced-intensity preparative regimen , evaluate survival , evaluate side effect include GVHD treatment . Patients study two year treatment active monitoring . All patient follow death .</detailed_description>
	<mesh_term>Anemia</mesh_term>
	<mesh_term>Anemia , Aplastic</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Fludarabine phosphate</mesh_term>
	<mesh_term>Fludarabine</mesh_term>
	<criteria>21 year old young Male female recipient must histopathologically confirm diagnosis severe aplastic anemia . Diagnostic Criteria Server Aplastic Anemia base definition set forth international Aplastic Anemia Study Group At least two follow : Absolute neutrophil count &lt; 0.5 x 109/L Platelet count &lt; 20 x 109 /L Anemia correct reticulocyte count &lt; 1 % AND Bone marrow cellularity &lt; 25 % , bone marrow cellularity &lt; 50 % few 30 % hematopoietic cell Availability HLA identical sibling Active uncontrolled infection HIV1 infection Pregnancy breastfeeding . DLCO &lt; 40 % predict Left Ventricular Ejection Fraction &lt; 40 % Performance scale Karnofsky &lt; =40 % Lansky &lt; =40 % patient &lt; 16 year old</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>21 Years</maximum_age>
	<verification_date>March 2012</verification_date>
	<keyword>Anemia , Severe , Aplastic , Reduced-Intensity , Allogeneic , Stem , Cell , Transplantation</keyword>
</DOC>